1. Autophagy Metabolic Enzyme/Protease
  2. Autophagy Endogenous Metabolite
  3. Ursolic acid

Ursolic acid  (Synonyms: Prunol; Urson; Malol)

Cat. No.: HY-N0140 Purity: 99.66%
Handling Instructions Technical Support

Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.

For research use only. We do not sell to patients.

Ursolic acid Chemical Structure

Ursolic acid Chemical Structure

CAS No. : 77-52-1

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Ursolic acid:

Top Publications Citing Use of Products

    Ursolic acid purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847.  [Abstract]

    HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.

    Cellular Effect
    Cell Line Type Value Description References
    4T1 IC50
    44.08 μM
    Compound: 2; UA
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    518A2 EC50
    14.7 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    518A2 EC50
    14.7 μM
    Compound: UA
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    518A2 EC50
    14.7 μM
    Compound: UA
    Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    518A2 EC50
    14.7 μM
    Compound: 2; UA
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    8505C EC50
    13.5 μM
    Compound: 1
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    [PMID: 28033541]
    8505C EC50
    13.5 μM
    Compound: UA
    Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    A2780 EC50
    11.7 μM
    Compound: UA
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    A2780 EC50
    11.7 μM
    Compound: 1
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A2780 EC50
    11.7 μM
    Compound: UA
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    A2780 EC50
    11.7 μM
    Compound: 2; UA
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A-375 IC50
    30.88 μM
    Compound: 2; UA
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A549 IC50
    11.4 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    A549 EC50
    15.5 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    A549 EC50
    15.5 μM
    Compound: UA
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    A549 EC50
    15.5 μM
    Compound: UA
    Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    A549 EC50
    15.5 μM
    Compound: 2; UA
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    A549 IC50
    18.42 μM
    Compound: 2; UA
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    A549 IC50
    21.6 μM
    Compound: 3
    Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
    Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
    [PMID: 15730243]
    A549 IC50
    33 μM
    Compound: 1
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 26854375]
    A549 IC50
    33 μM
    Compound: 4
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine-B assay
    Growth inhibition of human A549 cells after 48 hrs by sulforhodamine-B assay
    [PMID: 23811086]
    A549 IC50
    35.79 μM
    Compound: UA; 1
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30108853]
    A549 IC50
    35.79 μM
    Compound: UA
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    A549 IC50
    55.8 μM
    Compound: 3
    Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
    [PMID: 15730243]
    A549 IC50
    74.65 μM
    Compound: UA
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    A549 IC50
    77.65 μM
    Compound: 2; UA
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    AGS IC50
    20.6 μM
    Compound: UA 5
    Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 28754470]
    AGS IC50
    20.6 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    Cytotoxicity against human AGS cells after 48 hrs by MTT assay
    [PMID: 22370266]
    AGS IC50
    43.3 μM
    Compound: UA 5
    Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    ASPC1 IC50
    12.6 μM
    Compound: 1
    Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
    Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    B16 IC50
    3.1 μM
    Compound: 23
    Growth inhibition of mouse B16 2F2 cells after 3 days
    Growth inhibition of mouse B16 2F2 cells after 3 days
    [PMID: 12027734]
    B16-F10 IC50
    20.08 μM
    Compound: 2; UA
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    Bcap37 IC50
    28.69 μM
    Compound: 1, UA, Ursolic acid
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
    [PMID: 23124210]
    Bel-7402 IC50
    64.64 μM
    Compound: 2; UA
    Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    BGC-823 IC50
    > 10 μM
    Compound: 1, Ursolic acid,UA
    Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
    Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
    [PMID: 19091579]
    BGC-823 IC50
    22.96 μM
    Compound: UA, Ursolic acid
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 21664827]
    BGC-823 IC50
    66.38 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
    [PMID: 21514015]
    Ca9-22 IC50
    5.9 μg/mL
    Compound: 8
    Cytotoxicity against human Ca9-22 cells after 24 hrs by MTT assay
    Cytotoxicity against human Ca9-22 cells after 24 hrs by MTT assay
    [PMID: 19534471]
    CAPAN-1 IC50
    8.6 μM
    Compound: UA
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    CEM-SS CC50
    21.9 μM
    Compound: 6
    Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
    Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
    [PMID: 15217281]
    CHO EC50
    1.43 μM
    Compound: 3
    Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
    Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
    [PMID: 19911773]
    COS-1 EC50
    0 μM
    Compound: 3
    Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
    Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
    [PMID: 19911773]
    DU-145 IC50
    11.1 μg/mL
    Compound: 1
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    Epithelial cell IC50
    > 20 μM
    Compound: ursolic acid
    Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
    Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
    [PMID: 18826277]
    FaDu EC50
    14.2 μM
    Compound: UA
    Cytotoxicity against human FADU cells after 96 hrs by SRB assay
    Cytotoxicity against human FADU cells after 96 hrs by SRB assay
    [PMID: 26750249]
    FaDu EC50
    14.2 μM
    Compound: 2; UA
    Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    GES1 IC50
    93.83 μM
    Compound: UA, Ursolic acid
    Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
    [PMID: 21664827]
    H9 IC50
    14.3 μM
    Compound: 6
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
    [PMID: 11141100]
    H9 EC50
    2 μg/mL
    Compound: 6
    Cytotoxicity against mock-infected human H9 cells after 4 days
    Cytotoxicity against mock-infected human H9 cells after 4 days
    [PMID: 9748372]
    H9 IC50
    6.5 μg/mL
    Compound: 6
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
    [PMID: 9748372]
    HCT-116 IC50
    17.7 μM
    Compound: UA
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    HCT-116 IC50
    19 μM
    Compound: UA
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31771799]
    HCT-116 IC50
    38.78 μM
    Compound: UA
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    HCT-116 IC50
    42 μM
    Compound: 1
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 26854375]
    HCT-116 IC50
    42 μM
    Compound: 4
    Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine-B assay
    Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine-B assay
    [PMID: 23811086]
    HEK293 IC50
    1.9 μM
    Compound: 9
    Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
    Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
    [PMID: 20100662]
    HeLa IC50
    > 10 μM
    Compound: 1, Ursolic acid,UA
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
    [PMID: 19091579]
    HeLa IC50
    > 40 μM
    Compound: 1; UA
    Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 28733083]
    HeLa IC50
    11.1 μg/mL
    Compound: 1
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    HeLa IC50
    33.1 μM
    Compound: UA 5
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    HeLa IC50
    33.12 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    [PMID: 21514015]
    HeLa IC50
    64.48 μM
    Compound: UA
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    Hep 3B2 IC50
    23.8 μM
    Compound: UA
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 31006525]
    Hep 3B2 IC50
    23.8 μM
    Compound: UA; 1
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
    [PMID: 30728113]
    HepG2 IC50
    > 10 μM
    Compound: 22
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    HepG2 CC50
    113.62 μM
    Compound: UA
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 29326018]
    HepG2 IC50
    145 μM
    Compound: 3
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    HepG2 IC50
    15 μM
    Compound: 1
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    HepG2 IC50
    30.21 μM
    Compound: UA
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    HepG2 IC50
    40.2 μM
    Compound: 9
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    HepG2 EC50
    41.31 μM
    Compound: UA
    Agonist activity at human recombinant PPARalpha expressed in HepG2 cells co-transfected with pGL3-PPRE3-TK-luc reporter assessed as beta-galactosidase activity after 24 hrs by luciferase based transactivation assay
    Agonist activity at human recombinant PPARalpha expressed in HepG2 cells co-transfected with pGL3-PPRE3-TK-luc reporter assessed as beta-galactosidase activity after 24 hrs by luciferase based transactivation assay
    [PMID: 21855333]
    HepG2 IC50
    53.4 μM
    Compound: UA 5
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 28754470]
    HepG2 IC50
    53.4 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 22370266]
    HepG2 IC50
    53.42 μM
    Compound: UA, Ursolic acid
    Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
    [PMID: 21664827]
    HepG2 IC50
    68.8 μM
    Compound: UA 5
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    [PMID: 28754470]
    HepG2 IC50
    68.82 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 21514015]
    HepG2 2.2.15 CC50
    1537.8 μM
    Compound: A1; UA
    Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
    Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
    [PMID: 29627260]
    HL-60 IC50
    > 40 μM
    Compound: 1; UA
    Growth inhibition of human HL60 cells after 48 hrs by MTT assay
    Growth inhibition of human HL60 cells after 48 hrs by MTT assay
    [PMID: 28073673]
    HL-60 IC50
    21 μM
    Compound: UA
    Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
    [PMID: 15620242]
    HL-60 IC50
    8.7 μg/mL
    Compound: 8
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    [PMID: 19534471]
    HL-60 IC50
    9.5 μM
    Compound: UA
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    HMEC IC50
    39.3 μM
    Compound: UA 5
    Cytotoxicity in human HMEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human HMEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    HMV-2 cell line CC50
    145.9 μM
    Compound: 5
    Cytotoxicity against HMVII cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against HMVII cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 27020521]
    HMV-2 cell line CC50
    69.5 μM
    Compound: 5
    Cytotoxicity against HMVII cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against HMVII cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27020521]
    HT-29 EC50
    10.6 μM
    Compound: UA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    HT-29 EC50
    10.6 μM
    Compound: 1
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    HT-29 EC50
    10.6 μM
    Compound: UA
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    HT-29 EC50
    10.6 μM
    Compound: UA
    Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    HT-29 EC50
    10.6 μM
    Compound: 2; UA
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    HT-29 IC50
    11.1 μg/mL
    Compound: 1
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    HT-29 IC50
    25.3 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    [PMID: 22370266]
    HT-29 IC50
    25.3 μM
    Compound: UA 5
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    HT-29 IC50
    26.31 μM
    Compound: UA, Ursolic acid
    Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
    [PMID: 21664827]
    HT-29 IC50
    3.5 μM
    Compound: 1
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    [PMID: 30057155]
    J774 IC50
    13.1 μM
    Compound: 7
    Cytotoxicity against mouse J774 cells by alamar blue assay
    Cytotoxicity against mouse J774 cells by alamar blue assay
    [PMID: 17637068]
    K562 IC50
    10.2 μM
    Compound: UA
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    K562 IC50
    41.01 μM
    Compound: 2; UA
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    K562/Adr IC50
    38.06 μM
    Compound: 2; UA
    Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    KB ED50
    3.76 μg/mL
    Compound: ursolic acid
    Cytotoxicity against human KB cells by microassay
    Cytotoxicity against human KB cells by microassay
    [PMID: 2380724]
    KB IC50
    31.8 μM
    Compound: 9
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    KB ED50
    8.3 μM
    Compound: 3, UA
    Cytotoxicity against human KB cells by sulforhodamine B assay
    Cytotoxicity against human KB cells by sulforhodamine B assay
    [PMID: 17591444]
    L02 IC50
    > 100 μM
    Compound: UA
    Cytotoxicity against human HL7702 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HL7702 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    L02 IC50
    > 50 μM
    Compound: UA; 1
    Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
    [PMID: 30108853]
    L02 IC50
    58.37 μM
    Compound: 2; UA
    Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    Lewis lung carcinoma cell line IC50
    23.37 μM
    Compound: 2; UA
    Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    LN-229 IC50
    47.4 μM
    Compound: UA
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    Lu1 IC50
    11.5 μM
    Compound: 9
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    MCF7 IC50
    > 30 μM
    Compound: Ursolic acid
    Cytotoxicity against human MCF7 cells by WST-1 assay
    Cytotoxicity against human MCF7 cells by WST-1 assay
    [PMID: 19836230]
    MCF7 IC50
    > 30 μM
    Compound: Ursolic acid
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
    [PMID: 19836230]
    MCF7 IC50
    > 30 μM
    Compound: Ursolic acid
    Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
    Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
    [PMID: 19836230]
    MCF7 IC50
    12.3 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    MCF7 EC50
    12.7 μM
    Compound: UA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    MCF7 EC50
    12.7 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    MCF7 EC50
    12.7 μM
    Compound: UA
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    MCF7 EC50
    12.7 μM
    Compound: UA
    Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
    [PMID: 26177446]
    MCF7 EC50
    12.7 μM
    Compound: 2; UA
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    MCF7 GI50
    21 μM
    Compound: UA 5
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    MCF7 IC50
    37 μM
    Compound: 1
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 26854375]
    MCF7 IC50
    37 μM
    Compound: 4
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine-B assay
    Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine-B assay
    [PMID: 23811086]
    MCF7 IC50
    44.84 μM
    Compound: UA
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
    [PMID: 26343825]
    MCF7 IC50
    6.6 μM
    Compound: 22
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    MCF7 IC50
    70.12 μM
    Compound: 2; UA
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 31673307]
    MCF7 IC50
    9.3 μM
    Compound: 9
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
    [PMID: 28318944]
    MDA-MB-231 IC50
    > 30 μM
    Compound: Ursolic acid
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
    [PMID: 19836230]
    MDA-MB-231 IC50
    > 40 μM
    Compound: 1; UA
    Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 28733083]
    MDA-MB-231 GI50
    11.1 μM
    Compound: UA 5
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
    [PMID: 28754470]
    MDA-MB-231 IC50
    5.9 μM
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    MDA-MB-231 IC50
    70.27 μM
    Compound: 2; UA
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    MDA-MB-435 IC50
    13.1 μg/mL
    Compound: 1
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    MGC-803 IC50
    24.32 μM
    Compound: 1, UA, Ursolic acid
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    [PMID: 23124210]
    MGC-803 IC50
    27.08 μM
    Compound: UA
    Cytotoxicity against human MGC803 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    MGC-803 IC50
    27.58 μM
    Compound: UA; 1
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    [PMID: 30108853]
    MIA PaCa-2 IC50
    10.4 μM
    Compound: 1
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    NCI-H460 IC50
    14.8 μM
    Compound: 1; UA
    Cytotoxicity against human NCI-H460 cells expressing CTR5 gene assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human NCI-H460 cells expressing CTR5 gene assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
    [PMID: 27484517]
    NCI-H460 IC50
    16.2 μM
    Compound: UA
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    [PMID: 34352711]
    NCI-H460 IC50
    21.1 μM
    Compound: 1; UA
    Cytotoxicity against human LKB1-positive NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
    Cytotoxicity against human LKB1-positive NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
    [PMID: 27484517]
    NCI-H460 IC50
    30.8 μM
    Compound: 1; UA
    Cytotoxicity against human NCI-H460 spheroids expressing CTR5 gene assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescence viability assay
    Cytotoxicity against human NCI-H460 spheroids expressing CTR5 gene assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescence viability assay
    [PMID: 27484517]
    NCI-H460 IC50
    32.17 μM
    Compound: UA; 1
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
    [PMID: 30108853]
    NCI-N87 IC50
    4.2 μM
    Compound: 22
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
    [PMID: 27797185]
    Neutrophil IC50
    0.6 μg/mL
    Compound: 21
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
    [PMID: 28218000]
    Neutrophil IC50
    0.8 μg/mL
    Compound: 21
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
    [PMID: 28218000]
    Neutrophil IC50
    2.79 μg/mL
    Compound: 5
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide-anion generation incubated for 5 mins prior to FMLP/CB-challenge measured after 10 mins by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide-anion generation incubated for 5 mins prior to FMLP/CB-challenge measured after 10 mins by spectrophotometry
    [PMID: 22429052]
    Neutrophil IC50
    5.21 μg/mL
    Compound: 5
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using Meo-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry
    Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using Meo-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry
    [PMID: 22429052]
    NIH3T3 EC50
    13.1 μM
    Compound: UA
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
    [PMID: 31718946]
    NIH3T3 EC50
    18.7 μM
    Compound: 1
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 28033541]
    NIH3T3 EC50
    18.7 μM
    Compound: UA
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    [PMID: 26750249]
    NIH3T3 EC50
    18.7 μM
    Compound: 2; UA
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
    [PMID: 27149037]
    NTUB1 IC50
    29.44 μM
    Compound: 1
    Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
    Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
    [PMID: 19758808]
    OVCAR-3 IC50
    12.9 μg/mL
    Compound: 1
    Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    [PMID: 30057155]
    PANC-1 IC50
    14.9 μM
    Compound: 1
    Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
    Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    PANC-1 IC50
    58.03 μM
    Compound: 2; UA
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 30433783]
    PC-3 IC50
    > 10 μg/mL
    Compound: 5
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
    [PMID: 22429052]
    PC-3 IC50
    20.8 μM
    Compound: 1
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    [PMID: 22959527]
    PC-3 IC50
    22.3 μM
    Compound: UA 5
    Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 28754470]
    PC-3 IC50
    22.3 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    [PMID: 22370266]
    Platelet IC50
    > 50 μg/mL
    Compound: Ursolic acid
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    Platelet IC50
    34.53 μg/mL
    Compound: Ursolic acid
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    PLC-PRF-5 ED50
    3.89 μg/mL
    Compound: ursolic acid
    Cytotoxicity against human PLC/PRF/5 cells by microassay
    Cytotoxicity against human PLC/PRF/5 cells by microassay
    [PMID: 2380724]
    RAW264.7 IC50
    > 50 μM
    Compound: 1
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    [PMID: 22079762]
    RAW264.7 IC50
    13.8 μM
    Compound: UA
    Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
    Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
    [PMID: 35175765]
    RAW264.7 IC50
    46.9 μM
    Compound: Ursolic acid
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
    Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
    [PMID: 14510614]
    RAW264.7 IC50
    58.5 μM
    Compound: Ursolic acid
    Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
    Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
    [PMID: 14510614]
    Sf21 IC50
    > 40 μM
    Compound: 23
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
    [PMID: 31774676]
    SH-SY5Y IC50
    54.62 μM
    Compound: 1, UA, Ursolic acid
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
    [PMID: 21514015]
    SK-OV-3 IC50
    > 10 μM
    Compound: 1, Ursolic acid,UA
    Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
    [PMID: 19091579]
    SMMC-7721 IC50
    > 40 μM
    Compound: 1; UA
    Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
    Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
    [PMID: 28733083]
    T-24 IC50
    29.29 μM
    Compound: UA; 1
    Cytotoxicity against human T24 cells after 48 hrs by MTT assay
    Cytotoxicity against human T24 cells after 48 hrs by MTT assay
    [PMID: 30108853]
    T-24 IC50
    29.29 μM
    Compound: UA
    Cytotoxicity against human T24 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human T24 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25841199]
    THP-1 IC50
    9.1 μM
    Compound: 1
    Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
    Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
    [PMID: 26854375]
    THP-1 IC50
    9.1 μM
    Compound: 4
    Growth inhibition of human THP1 cells after 48 hrs by sulforhodamine-B assay
    Growth inhibition of human THP1 cells after 48 hrs by sulforhodamine-B assay
    [PMID: 23811086]
    Vero CC50
    31.9 μM
    Compound: 5
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 27020521]
    Vero CC50
    35.9 μM
    Compound: 5
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27020521]
    Vero CC50
    99.91 μM
    Compound: UA
    Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
    [PMID: 29326018]
    WI-38 IC50
    1.8 μM
    Compound: 3
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    WI-38 VA13 IC50
    93.6 μM
    Compound: 3
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
    [PMID: 15730243]
    Z-138 IC50
    9.8 μM
    Compound: UA
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    [PMID: 34352711]
    In Vitro

    Ursolic acid induces phosphorylation of AMP-activated protein kinase alpha (AMPKα) and suppressed the protein expression of DNA methyltransferase 1 (DNMT1) in the dose-dependent manner[1].
    The combination of Ursolic acid (0.5 μM) and Leucine (10 μM) prove to be the most effective in promoting myogenic differentiation. The combination of Ursolic acid and Leucine significantly increase CK activity than treatment with either agent alone. The level of myosin heavy chain, a myogenic differentiation marker protein, is also enhanced by the combination of Ursolic acid and Leucine[2].
    Ursolic acid efficiently induces apoptosis, possibly via the downregulation of B-cell lymphoma 2 (Bcl-2), the upregulation of Bcl-2-associated X protein and the proteolytic activation of caspase-3. Furthermore, the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase is increased by the administration of ursolic acid. In addition, Ursolic acid significantly suppresses the invasive phenotype of the SNU-484 cells and significantly decreases the expression of matrix metalloproteinase (MMP)-2[3].
    Ursolic acid (UA) potently induces the apoptosis of gastric cancer SGC-7901 cells. Further mechanistic studies revealed that the ROCK1/PTEN signaling pathway plays a critical role in Ursolic acid-mediated mitochondrial translocation of cofilin-1 and apoptosis[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Ursolic acid treatment markedly improves the survival of septic rats, and attenuated CLP-induced lung injury, including reduction of lung wet/dry weight ratio, infiltration of leukocytes and proteins, myeloperoxidase activity, and malondialdehyde content. In addition, Ursolic acid significantly decreases the serum levels of tumor necrosis factor-α, interleukin-6, and interleukin-1β, inhibits the expression of inducible nitric oxide synthase and cyclooxygenase-2 in the lung, which are involved in the productions of nitric oxide and prostaglandin E2[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    456.70

    Formula

    C30H48O3

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (72.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1896 mL 10.9481 mL 21.8962 mL
    5 mM 0.4379 mL 2.1896 mL 4.3792 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% HP-β-CD in Saline

      Solubility: 6.67 mg/mL (14.60 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.66%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1896 mL 10.9481 mL 21.8962 mL 54.7405 mL
    5 mM 0.4379 mL 2.1896 mL 4.3792 mL 10.9481 mL
    10 mM 0.2190 mL 1.0948 mL 2.1896 mL 5.4741 mL
    15 mM 0.1460 mL 0.7299 mL 1.4597 mL 3.6494 mL
    20 mM 0.1095 mL 0.5474 mL 1.0948 mL 2.7370 mL
    25 mM 0.0876 mL 0.4379 mL 0.8758 mL 2.1896 mL
    30 mM 0.0730 mL 0.3649 mL 0.7299 mL 1.8247 mL
    40 mM 0.0547 mL 0.2737 mL 0.5474 mL 1.3685 mL
    50 mM 0.0438 mL 0.2190 mL 0.4379 mL 1.0948 mL
    60 mM 0.0365 mL 0.1825 mL 0.3649 mL 0.9123 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ursolic acid
    Cat. No.:
    HY-N0140
    Quantity:
    MCE Japan Authorized Agent: